Mechanistic modeling of empty-full separation in recombinant adeno-associated virus production using anion-exchange membrane chromatography

被引:8
|
作者
Gomis-Fons, Joaquin [1 ]
Zee, Bryan [2 ]
Hurwit, Daniel [2 ]
Woo, James [2 ]
Moscariello, John [2 ,3 ]
Nilsson, Bernt [1 ,4 ]
机构
[1] Lund Univ, Dept Chem Engn, Lund, Scania, Sweden
[2] Bristol Myers Squibb, Gene Delivery Proc & Analyt Dev, Seattle, WA USA
[3] Bristol Myers Squibb, Gene Delivery Proc & Analyt Dev, Seattle, WA 98102 USA
[4] Lund Univ, Dept Chem Engn, SE-22100 Lund, Sweden
关键词
adeno-associated virus; downstream process development; empty-full separation; full capsid enrichment; mechanistic modeling; membrane chromatography; VECTORS; DESIGN; CHARGE; STEP;
D O I
10.1002/bit.28595
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Recombinant adeno-associated viral vectors (rAAVs) have become an industry-standard technology in the field of gene therapy, but there are still challenges to be addressed in their biomanufacturing. One of the biggest challenges is the removal of capsid species other than that which contains the gene of interest. In this work, we develop a mechanistic model for the removal of empty capsids-those that contain no genetic material-and enrichment of full rAAV using anion-exchange membrane chromatography. The mechanistic model was calibrated using linear gradient experiments, resulting in good agreement with the experimental data. The model was then applied to optimize the purification process through maximization of yield studying the impact of mobile phase salt concentration and pH, isocratic wash and elution length, flow rate, percent full (purity) requirement, loading density (challenge), and the use of single-step or two-step elution modes. A solution from the optimization with purity of 90% and recovery yield of 84% was selected and successfully validated, as the model could predict the recovery yield with remarkable fidelity and was able to find process conditions that led to significant enrichment. This is, to the best of our knowledge, the first case study of the application of de novo mechanistic modeling for the enrichment of full capsids in rAAV manufacturing, and it serves as demonstration of the potential of mechanistic modeling in rAAV process development.
引用
收藏
页码:719 / 734
页数:16
相关论文
共 50 条
  • [41] Cation-exchange high-performance liquid chromatography of recombinant adeno-associated virus type 2
    Debelak, D
    Fisher, J
    Iuliano, S
    Sesholtz, D
    Sloane, DL
    Atkinson, EM
    JOURNAL OF CHROMATOGRAPHY B, 2000, 740 (02): : 195 - 202
  • [42] Assessment of the percentage of full recombinant adeno-associated virus particles in a gene therapy drug using CryoTEM
    Colomb-Delsuc, Mathieu
    Raim, Roman
    Fiedler, Christian
    Reuberger, Stefan
    Lengler, Johannes
    Nordstrom, Rickard
    Ryner, Martin
    Folea, Ioana Mihaela
    Kraus, Barbara
    Bort, Juan A. Hernandez
    Sintorn, Ida-Maria
    PLOS ONE, 2022, 17 (06):
  • [43] Development and Validation of an Anion Exchange High-Performance Liquid Chromatography Method for Analysis of Empty Capsids and Capsids Encapsidating Genetic Material in a Purified Preparation of Recombinant Adeno-Associated Virus Serotype 5
    Joshi, Pranav R. H.
    Bernier, Alice
    Chahal, Parminder S.
    Kamen, Amine
    HUMAN GENE THERAPY, 2021, 32 (21-22) : 1390 - 1402
  • [44] ACUVRA: Anion-Exchange Chromatography UV-Ratio Analysis-A QC-Friendly Method for Monitoring Adeno-Associated Virus Empty Capsid Content To Support Process Development and GMP Release Testing
    Frenkel, Ruth
    Tribby, Dana
    Boumajny, Boris
    Larson, Nicholas
    Sampson, Matthew
    Barney, Christopher
    Bergelson, Svetlana
    Sosic, Zoran
    Yeung, Bernice
    AAPS JOURNAL, 2022, 25 (01):
  • [45] Comparing CsCl Density Gradient Ultracentrifugation and Anion Exchange Chromatography for Full Capsid Enrichment of a Novel Adeno-Associated Viral Vector
    Facendola, Roberto
    Bodige, Kavitha
    Guzman, Jacob
    Carroll, Patrick
    Nguyen, Kevin
    Elich, Tom
    Sharma, Shamik
    Dhanasekharan, Kumar
    MOLECULAR THERAPY, 2024, 32 (04) : 499 - 499
  • [46] Production of Recombinant Adeno-Associated Virus Type 1 Vector Using a Herpes Simplex Virus Based System
    Kang, Wen
    Drogemuller, Chris
    Scotti, Marina M.
    Ye, Guo-jie
    MOLECULAR THERAPY, 2006, 13 : S195 - S195
  • [47] Production of recombinant adeno-associated virus 5 using a novel self-attenuating adenovirus production platform
    Roach, Matthew K.
    Wirz, Phillip
    Rouse, Jeremy
    Schorzman, Allison
    Beard, Clayton W.
    Scott, David
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2024, 32 (03)
  • [48] Size Exclusion Chromatography with Dual Wavelength Detection as a Sensitive and Accurate Method for Determining the Empty and Full Capsids of Recombinant Adeno-Associated Viral Vectors
    Meng, He
    Sorrentino, Michelle
    Woodcock, Denise
    O'Riordan, Catherine
    Dhawan, Vijender
    Verhagen, Marc
    Davies, Claire
    HUMAN GENE THERAPY, 2022, 33 (3-4) : 202 - 212
  • [49] Scalable recombinant adeno-associated virus vector production in insect cells using a single baculovirus construct
    de Jong, L. A.
    van Tongeren, H. M.
    Sanders, B. P.
    van Oers, M. M.
    Pijlman, G. P.
    HUMAN GENE THERAPY, 2024, 35 (3-4) : A76 - A76
  • [50] Removal of Empty Particles from Type 1 Adeno-Associated Virus Vector Stocks by Ion Exchange Chromatography Potentiates Transgene Expression
    Urabe, Masashi
    Xin, Ke-Qin
    Obara, Yoko
    Nakakura, Takayo
    Mizukami, Hiroaki
    Kume, Akihiro
    Okuda, Kenji
    Ozawa, Keiya
    MOLECULAR THERAPY, 2006, 13 : S427 - S427